World's Best Scientists 2026 revealed!
Malcolm David Mason

Malcolm David Mason

D-Index & Metrics

Medicine

D-Index
106
Citations
62083
World Ranking
6378
National Ranking
620

Overview

Malcolm David Mason is affiliated with Cardiff University in the United Kingdom. Their research primarily spans the field of Medicine, with a strong focus on subfields such as Pulmonary and Respiratory Medicine, Oncology, Surgery, Radiology, Nuclear Medicine and Imaging, and Internal Medicine.

Their work covers multiple topics, prominently including Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, and Bladder and Urothelial Cancer Treatments. Additional research interests involve Radiopharmaceutical Chemistry and Applications, Venous Thromboembolism Diagnosis and Management, Hormonal and Reproductive Studies, and Colorectal Cancer Screening and Detection.

Malcolm David Mason has coauthored publications with several frequent collaborators. These include:

  • Silke Gillessen
  • Nicolas Mottet
  • Philip Cornford
  • Thomas Wiegel
  • Thomas Van den Broeck

The scientist has contributed articles to various publication venues. The most common among these are:

  • European Urology
  • The Lancet Oncology
  • British Journal of Urology
  • European Urology Focus
  • British Journal of Cancer

Some of their recent papers include:

  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent, 2020, European Urology
  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer, 2020, European Urology
  • Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer, 2023, New England Journal of Medicine
  • Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review, 2020, European Urology
  • Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer, 2021, JAMA Oncology

Best Publications

  • EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

    Freddie C. Hamdy;Jenny L. Donovan;J. Athene Lane;Malcolm Mason

  • EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

    Axel Heidenreich;Patrick J. Bastian;Joaquim Bellmunt;Michel Bolla

  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Nicolas Mottet;Roderick C.N. van den Bergh;Erik Briers;Thomas Van den Broeck

  • EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

    Axel Heidenreich;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

    Philip Cornford;Joaquim Bellmunt;Michel Bolla;Erik Briers

  • EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer ☆

    Nicolas Mottet;Joaquim Bellmunt;Michel Bolla;Steven Joniau

  • 前立腺癌のEAUガイドライン。パート1:臨床的限局性疾患のスクリーニング,診断および治療

    A Heidenreich;J Bellmunt;M Bolla;S Joniau

  • Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

    Donovan Jl;Hamdy Fc;Lane Ja;Mason M

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Cancer exosomes trigger fibroblast to myofibroblast differentiation

    Jason P. Webber;Robert Steadman;Malcolm David Mason;Zsuzsanna Tabi

  • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

    Philip Cornford;Roderick C.N. van den Bergh;Erik Briers;Thomas Van den Broeck

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

    Padraig Warde;Malcolm David Mason;Keyue Ding;Peter Kirkbride

  • European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

    H. J. Schmoll;R. Souchon;S. Krege;P. Albers

  • Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression

    Aled Clayton;J. Paul Mitchell;Jacquelyn Court;Seamus Linnane

  • Guía de la EAU sobre el cáncer de próstata: Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;Joaquim Bellmunt;M. Bolla;S. Joniau

  • EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer - Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración

    N. Mottet;J. Bellmunt;M. Bolla;S. Joniau

Frequent Co-Authors

Wen Guo Jiang
Wen Guo Jiang Cardiff University
Matthew R. Sydes
Matthew R. Sydes University College London
Nicholas D. James
Nicholas D. James Institute of Cancer Research
David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Silke Gillessen
Silke Gillessen Universita della Svizzera Italiana
Mahesh K. B. Parmar
Mahesh K. B. Parmar University College London
Chris Parker
Chris Parker Institute of Cancer Research
Timothy J Wilt
Timothy J Wilt University of Minnesota
David E. Neal
David E. Neal University of Cambridge

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in alternative or supplementary pathways to a career in healthcare, there are numerous flexible and affordable online options available. One popular route is pursuing affordable nursing programs online, which allow students to learn at their own pace while preparing for rewarding roles in patient care.

Registered nurses seeking higher credentials can explore the cheapest bsn programs to enhance their qualifications and job prospects. For those aiming for leadership, nurse practitioner, or teaching positions, the cheapest dnp programs offer an efficient way to earn a terminal degree in nursing without breaking the bank.

Individuals with non-nursing backgrounds who are considering a career change can benefit from online msn programs for non nurses, bridging the transition into advanced nursing roles. These pathways provide flexibility, affordability, and a variety of specializations, making healthcare careers accessible to more people than ever before.

Best Scientists Citing Malcolm David Mason

Trending Scientists

Recently Published Articles